When it was announced that Nintendo was going to be released a fighting game with motion controls called Arms, many were concerned that the response wouldn’t be up to par. Based on early impressions, however, both the game and the controls seem to be performing well. This should come as a relief to fans of the Switch who might have been worried that its rise to fame might be derailed.
It’s no secret that the Nintendo Switch is on Cloud 9 right now, with the console breaking records at every turn and enthusiasm for ownership still sky high. However, even the smallest details can turn players off from a product and wonky motion controls could be a deal breaker for many. Fortunately, Kotaku and publications like it have judged that such concerns might be unwarranted.
Now, it’s worth noting that this is one game and the controls are about as straightforward as they can be. Even so, critics are still impressed by how well the characters respond to movements in order to perform three basic attacks in Arms.
For those who don’t know, Arms is basically a fighting game where players control characters who use extendable extremities to fight. Players can use both the normal controller scheme or the Joy-Con motion control and it was the latter that the reviewers focused on.
Suffice it to say, most of those who were lucky enough to test the game and the controls were surprised at how good it was. Granted, much of the excellence in the controls had a lot to do with how smart the developers were at taking advantage of the gyro-sensors, IGN notes. Whether it is punching, blocking or throwing, everything worked smoothly.
Of course, getting the hang of the controls does involve a learning curve, so players shouldn’t assume that the game will work perfectly for them without some practice. All in all, the Switch and Arms seem to perform admirably in an area where so much could have gone wrong. Players will know soon enough when the game comes out on June 16th.


US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 



